In this article, we will discuss Durvalumab (Warnings-16). So, let’s get started.
Immune-mediated adrenal insufficiency occurred in 0.5% (9/1889) of patients receiving Durvalumab, including Grade 3 (<0.1%) adverse reactions. Events resolved in 1 of the 9 patients and did not lead to permanent discontinuation of Durvalumab in any patients. Systemic corticosteroids were required in all patients with adrenal insufficiency; of these, the majority remained on systemic corticosteroids.